---
title: "Evommune Q2 FY26 net loss widens to $32.25 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295138729.md"
description: "Evommune reported a widened Q2 FY26 net loss of $32.25 million, up from $13.57 million in the prior year, with nil revenue. R&D expenses rose 34.49% to $26.41 million, and G&A expenses doubled to $8.48 million. Cash reserves increased to $288 million. The company anticipates top-line Phase 2b data for EVO756 in atopic dermatitis by September 2026 and migraine prophylaxis data in 2027."
datetime: "2026-08-06T20:17:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295138729.md)
  - [en](https://longbridge.com/en/news/295138729.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295138729.md)
generator: "portal-rs"
---

# Evommune Q2 FY26 net loss widens to $32.25 million

-   Evommune posted a Q2 net loss of USD 32.25 million, widening from USD 13.57 million a year earlier. \* R&D expense rose 34.49% to USD 26.41 million, while G&A expense more than doubled to USD 8.48 million. \* Revenue was nil, versus nil in the prior-year quarter. \* Cash, cash equivalents and investments totaled USD 288 million at June 30, up from USD 216.7 million at Dec. 31. \* Evommune expects EVO756 atopic dermatitis Phase 2b top-line data in September 2026; migraine prophylaxis Phase 2b top-line data is anticipated in 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608061605BIZWIRE\_USPR\_\_\_\_\_20260806\_BW006411) on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [EVMN.US](https://longbridge.com/en/quote/EVMN.US.md)
- [EVFM.US](https://longbridge.com/en/quote/EVFM.US.md)

## Related News & Research

- [Evommune posts corporate presentation outlining Phase 2 inflammation-drug pipeline focusing on EVO756, EVO301](https://longbridge.com/en/news/295150923.md)
- [Vuxen Group announces availability of FY2025/2026 annual report (May 1, 2025–April 30, 2026)](https://longbridge.com/en/news/297499193.md)
- [iShares Core S&P 500 ETF declares Q3 2026 distribution of R$ 0.10 per unit](https://longbridge.com/en/news/297548335.md)
- [Paratus Energy announces Q2 2026 cash dividend of USD 0.22 per share](https://longbridge.com/en/news/297268195.md)
- [Systemair corrects dividend record date to Aug. 31, 2026 from Sept. 31 error](https://longbridge.com/en/news/297344953.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**